NCT01480739View on ClinicalTrials.gov

AZD5069 Neutrophil Function Study

PHASE1CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions

Chemokine Receptor 2 (CXCR2) Antagonist

Interventions

DRUG

100 mg (50 mg x 2) AZD5069

Twice daily for 7 days

DRUG

100 mg Placebo

Twice daily for 7 days

Trial Locations (1)

Unknown

London

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY